Japan's Fujifilm gets $265 million U.S. contract to boost output of potential virus vaccine
Reuters
Published Jul 28, 2020 12:14AM ET
TOKYO (Reuters) - The United States has awarded a $265 million contract to a Texas facility of Japan's Fujifilm Holdings Corp to step up production of a coronavirus vaccine candidate, President Donald Trump said.
Trump made the announcement on Monday, as he toured another Fujifilm facility in North Carolina. The order widens a pact between the Department of Health and Human Services, the Texas A&M university system and Fujifilm Diosynth Biotechnologies.
The funds will speed by several months an expansion planned at the Texas facility in College Station, with completion now expected this fall, Fujifilm said in a news release.
Last week, Fujifilm Diosynth, a drug ingredient subsidiary of the Japanese firm, said it would make bulk drug substances for Novavax (NASDAQ:NVAX) Inc.'s virus vaccine candidate, NVX-CoV2373.
It added that it would spend $928 million to double capacity at a Denmark facility that is also involved in making virus treatments.
The company's shares climbed 3.2% in Tokyo in a flat overall market.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.